Rup Bonita, O'Hara Denise
Bioanalytical Research & Development, Drug Safety & Metabolism, Wyeth Research, Andover, MA 01867, USA.
AAPS J. 2007 May 11;9(2):E148-55. doi: 10.1208/aapsj0902016.
Throughout the life cycle of biopharmaceutical products, bioanalytical support is provided using ligand binding assays to measure the drug product for pharmacokinetic, pharmacodynamic, and immunogenicity studies. The specificity and selectivity of these ligand binding assays are highly dependent on the ligand binding reagents. Thus the selection, characterization, and management processes for ligand binding reagents are crucial to successful assay development and application. This report describes process considerations for selection and characterization of ligand binding reagents that are integral parts of the different phases of assay development. Changes in expression, purification, modification, and storage of the ligand binding reagents may have a profound effect on the ligand binding assay performance. Thus long-term management of the critical ligand binding assay reagents is addressed including suggested characterization criteria that allow ligand binding reagents to be used in as consistent a manner as possible. Examples of challenges related to the selection, modification, and characterization of ligand binding reagents are included.
在生物制药产品的整个生命周期中,使用配体结合测定法提供生物分析支持,以测量药物产品用于药代动力学、药效学和免疫原性研究。这些配体结合测定法的特异性和选择性高度依赖于配体结合试剂。因此,配体结合试剂的选择、表征和管理过程对于成功的测定法开发和应用至关重要。本报告描述了在测定法开发的不同阶段中作为组成部分的配体结合试剂的选择和表征的过程考量。配体结合试剂在表达、纯化、修饰和储存方面的变化可能会对配体结合测定法的性能产生深远影响。因此,本报告还讨论了关键配体结合测定试剂的长期管理,包括建议的表征标准,以使配体结合试剂能够尽可能以一致的方式使用。文中还列举了与配体结合试剂的选择、修饰和表征相关的挑战实例。